Email Contact Phone Company Visit Website

Location Office

Kungsgatan 36
Stockholm
SE

NASDAQ OMX New York Head Office

One Liberty Plaza
New York
NY
US

NASDAQ OMX Stockholm Office

Tullvaktsvägen 15
Stockholm
SE

NASDAQ OMX Rockville Office

805 King Farm Boulevard 1st and 2nd floor
Rockville
MD
US

NASDAQ OMX London Office

Woolgate Exchange, 25 Basinghall Street, City of London
London
GB

NASDAQ OMX New York Office

Marketsite 4 Times Square
New York
NY
US

NASDAQ OMX Hong Kong Office

Room 1207-8, 12/F Man Yee Building 68 Des Voeux Road Central Hong Kong
Hong Kong
HK

NASDAQ OMX Singapore Office

20 Collyer Quay, #17-01
Singapore
SG

NASDAQ OMX Chicago Office

One North Wacker Drive Suite 3600
Chicago
IL
US

NASDAQ OMX Belgium Office

Avenue de Cortenbergh 116
Brussels
BE

NASDAQ OMX Dubai Office

Dubai World Trade Centre Sheikh Zayed Road
Dubai
AE

NASDAQ OMX Tokyo Office

1F, Kojimachi Square Building Nibancho, 3 Chiyoda-ku, Tokyo
Tokyo
JP

NASDAQ OMX Boston Office

100 Franklin St
Boston
MA
US

Location Office

Level 17-19, 110 Bishopsgate
London
GB

Telephone

212 231 5018

Contact

Todd A Swearingen
[email protected]
Back to all NASDAQ OMX announcements

NASDAQ OMX Welcomes Diamyd Medical to First North

NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in Diamyd Medical AB (short name: DMYD B) shares commenced today on First North at NASDAQ OMX Stockholm. Diamyd Medical belongs to the Healthcare sector and is the eighth new company to be admitted to trading on First North in 2013.

Diamyd Medical is a diabetes company headquartered in Stockholm, Sweden. The company develops the diabetes vaccine Diamyd® and the active ingredient GAD for the treatment and prevention of type 1-diabetes. Two researcher-initiated Phase II studies with Diamyd® are ongoing. Diamyd Medical AB (formerly Diamyd Therapeutics AB) was recently spun out from the publicly traded Mertiva AB (formerly Diamyd Medical AB).

“The new company structure is well positioned to continue the work to find a cure for type 1-diabetes,” says Peter Zerhouni, CEO of Diamyd Medical. “As a separately listed entity on First North, Diamyd Medical is able to gain a stronger focus on the continued development of our diabetes vaccine while reaching out to a broad investor audience. We will also leverage our expertise and worldwide network in diabetes to assess the potential to expand our business in terms of products in the diabetes area.”

“We welcome Diamyd Medical to First North, one of Europe’s most liquid growth markets,” says Adam Kostyal, Senior Vice President at NASDAQ OMX. “We’ve experienced a marked inflow of life science companies and Diamyd is our fourth addition to the healthcare sector this year."

Diamyd Medical has appointed Remium Nordic AB as Certified Adviser.